Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 studyResearch in context by Marek Trněný, Abraham Avigdor, Matthew S. McKinney, Shankara Paneesha, Björn E. Wahlin, John S. Hrom, David Cunningham, Nicholas Morley, Miguel Canales, Mariana Bastos-Oreiro, David Belada, Liliana Devizzi, Fred Zheng, Douglas J. DeMarini, Wei Jiang, Ping Jiang, Ryan C. Lynch

Get full text

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 studyResearch in context by Pier Luigi Zinzani, Marek Trněný, Vincent Ribrag, Vittorio Ruggero Zilioli, Jan Walewski, Jacob Haaber Christensen, Vincent Delwail, Guillermo Rodriguez, Parameswaran Venugopal, Morton Coleman, Caroline Dartigeas, Caterina Patti, Fabrizio Pane, Wojciech Jurczak, Michal Taszner, Shankara Paneesha, Fred Zheng, Douglas J. DeMarini, Wei Jiang, Aidan Gilmartin, Amitkumar Mehta

Get full text

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma by Jessie Villanueva, Jeffrey R. Infante, Clemens Krepler, Patricia Reyes-Uribe, Minu Samanta, Hsin-Yi Chen, Bin Li, Rolf K. Swoboda, Melissa Wilson, Adina Vultur, Mizuho Fukunaba-Kalabis, Bradley Wubbenhorst, Thomas Y. Chen, Qin Liu, Katrin Sproesser, Douglas J. DeMarini, Tona M. Gilmer, Anne-Marie Martin, Ronen Marmorstein, David C. Schultz, David W. Speicher, Giorgos C. Karakousis, Wei Xu, Ravi K. Amaravadi, Xiaowei Xu, Lynn M. Schuchter, Meenhard Herlyn, Katherine L. Nathanson

Get full text